NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
DISOPHROL (dexbrompheniramine maleate; pseudoephedrine sulfate) by Merck & Co.. Approved for nasal congestion due to the common cold, hay fever, other upper repiratory allergies helps decongest sinus opening and 5 more indications.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Disophrol is an oral tablet combining dexbrompheniramine maleate (antihistamine) and pseudoephedrine sulfate (decongestant) for symptomatic relief of nasal congestion, hay fever, and upper respiratory allergies. The antihistamine blocks histamine receptors to reduce allergic symptoms including runny nose, sneezing, and itching, while the decongestant causes vasoconstriction to relieve sinus swelling and restore nasal airflow.
Pre-Launch
Pre-launch stage indicates early commercialization planning; commercial teams are likely small but growing with focus on launch readiness and market positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (8)
Worked on DISOPHROL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.